TuHURA Regains Nasdaq Compliance with $1.00 Share Price Over 11 Days
TuHURA regained Nasdaq compliance by closing at or above $1.00 for 11 consecutive business days ending Feb. 25, 2026, resolving its minimum bid price deficiency. The company is enrolling Phase 3 IFx-2.0 in Merkel cell carcinoma, preparing Phase 2 TBS-2025 in relapsed NPM1-mutated AML and advancing preclinical ADC programs.
1. Nasdaq Compliance Achievement
On February 26, 2026, TuHURA received written notice from Nasdaq confirming its common stock closed at or above $1.00 per share for 11 consecutive business days through February 25, 2026. This satisfied the minimum bid price requirement under Listing Rule 5550(a)(2), and Nasdaq has closed the compliance matter.
2. Clinical Pipeline Updates
TuHURA is enrolling patients in its randomized, placebo-controlled Phase 3 trial of IFx-2.0 plus Keytruda in first-line Merkel cell carcinoma. The company is preparing to initiate a Phase 2 study of its VISTA-inhibiting antibody TBS-2025 in relapsed/refractory NPM1-mutated AML and continues to advance preclinical first-in-class antibody drug conjugate programs.